MTG25 |
The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites
|
Medical technology guidance |
Infections: general and other
|
QS92 |
Smoking: harm reduction
|
Quality standards |
Smoking and tobacco
|
QS93 |
Atrial fibrillation: treatment and management
|
Quality standards |
Heart rhythm conditions
|
TA347 |
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
|
Technology appraisal guidance |
Lung cancer
|
TA346 |
Aflibercept for treating diabetic macular oedema
|
Technology appraisal guidance |
Macular oedema and retinal vein occlusion
|
TA348 |
Everolimus for preventing organ rejection in liver transplantation
|
Technology appraisal guidance |
Liver conditions: general and other
|
TA350 |
Secukinumab for treating moderate to severe plaque psoriasis
|
Technology appraisal guidance |
Psoriasis
|
IPG528 |
Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section
|
Interventional procedure guidance |
Intrapartum care
|
IPG529 |
Joint distraction for knee osteoarthritis without alignment correction
|
Interventional procedure guidance |
Knee conditions
|
TA349 |
Dexamethasone intravitreal implant for treating diabetic macular oedema
|
Technology appraisal guidance |
Macular oedema and retinal vein occlusion
|
TA351 |
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)
|
Technology appraisal guidance |
Acute coronary syndromes
|
TA345 |
Naloxegol for treating opioid‑induced constipation
|
Technology appraisal guidance |
Constipation
|
QS94 |
Obesity: prevention and lifestyle weight management in children and young people
|
Quality standards |
Diet, nutrition and obesity
|
QS96 |
Dyspepsia and gastro‑oesophageal reflux disease in adults: investigation and management
|
Quality standards |
Digestive tract conditions: general and other
|
QS95 |
Bipolar disorder in adults
|
Quality standards |
Bipolar disorder
|
QSD |
In development
Maternal and child nutrition - improving nutritional status
|
Quality standard |
Infants and neonates
|
MPG |
In development
Antimicrobial stewardship
|
Unclassified |
Antibiotic use
|
QSD |
In development
Drug allergy - diagnosis and management
|
Quality standard |
Blood and immune system conditions: general and other
|
CG |
In development
Melanoma
|
Guidelines |
Skin cancer
|
No hay comentarios:
Publicar un comentario